Omeros (OMER) Gains from Sales and Divestitures (2022 - 2023)
Omeros recorded quarterly Gains from Sales and Divestitures of $67250.0 in Q4 2023, down 31.9% quarter-over-quarter from $98750.0 in Q4 2022, and down 31.9% year-over-year from $98750.0 in Q4 2022.
Omeros' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $67250.0 for Q4 2023.
- In Q4 2023, Gains from Sales and Divestitures fell 31.9% year-over-year to $67250.0; the TTM figure through Dec 2023 stood at $67250.0 (down 31.9% YoY), while the FY2023 annual figure was $67250.0, down 31.9% from the prior year.
- Gains from Sales and Divestitures came in at $67250.0 for Q4 2023 at Omeros, down from $98750.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $98750.0 in Q4 2022 to a low of $67250.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 67,250.00 |
| Dec 31, 2023 | 67,250.00 |
| Dec 31, 2022 | 98,750.00 |
| Dec 31, 2022 | 98,750.00 |